These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 16305515)
1. The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. Melroy J; Nair V Curr Pharm Des; 2005; 11(29):3847-52. PubMed ID: 16305515 [TBL] [Abstract][Full Text] [Related]
2. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. Harrigan PR; Stone C; Griffin P; Nájera I; Bloor S; Kemp S; Tisdale M; Larder B J Infect Dis; 2000 Mar; 181(3):912-20. PubMed ID: 10720512 [TBL] [Abstract][Full Text] [Related]
3. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Daluge SM; Good SS; Faletto MB; Miller WH; St Clair MH; Boone LR; Tisdale M; Parry NR; Reardon JE; Dornsife RE; Averett DR; Krenitsky TA Antimicrob Agents Chemother; 1997 May; 41(5):1082-93. PubMed ID: 9145874 [TBL] [Abstract][Full Text] [Related]
4. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L; Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417 [TBL] [Abstract][Full Text] [Related]
5. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Ait-Khaled M; Rakik A; Griffin P; Cutrell A; Fischl MA; Clumeck N; Greenberg SB; Rubio R; Peters BS; Pulido F; Gould J; Pearce G; Spreen W; Tisdale M; Lafon S; Antivir Ther; 2002 Mar; 7(1):43-51. PubMed ID: 12008787 [TBL] [Abstract][Full Text] [Related]
6. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Ray AS; Yang Z; Shi J; Hobbs A; Schinazi RF; Chu CK; Anderson KS Biochemistry; 2002 Apr; 41(16):5150-62. PubMed ID: 11955063 [TBL] [Abstract][Full Text] [Related]
7. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586 [TBL] [Abstract][Full Text] [Related]
8. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585 [TBL] [Abstract][Full Text] [Related]
9. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. McGuigan C; Harris SA; Daluge SM; Gudmundsson KS; McLean EW; Burnette TC; Marr H; Hazen R; Condreay LD; Johnson L; De Clercq E; Balzarini J J Med Chem; 2005 May; 48(10):3504-15. PubMed ID: 15887959 [TBL] [Abstract][Full Text] [Related]
10. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287 [TBL] [Abstract][Full Text] [Related]
12. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848 [TBL] [Abstract][Full Text] [Related]
13. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801 [TBL] [Abstract][Full Text] [Related]
14. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M; Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623 [TBL] [Abstract][Full Text] [Related]
16. High Prevalence of Abacavir-associated L74V/I Mutations in Kenyan Children Failing Antiretroviral Therapy. Dziuban EJ; DeVos J; Ngeno B; Ngugi E; Zhang G; Sabatier J; Wagar N; Diallo K; Nganga L; Katana A; Yang C; Rivadeneira ED; Mukui I; Odhiambo F; Redfield R; Raizes E Pediatr Infect Dis J; 2017 Aug; 36(8):758-760. PubMed ID: 28383390 [TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847 [TBL] [Abstract][Full Text] [Related]
18. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485 [TBL] [Abstract][Full Text] [Related]
19. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Stürmer M; Staszewski S; Doerr HW Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153 [TBL] [Abstract][Full Text] [Related]
20. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment. Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]